ACC-Adrenocortical carcinoma; BLCA-Bladder Urothelial Carcinoma; ESCA-Esophageal carcinoma; BRCA-Breast invasive carcinoma; CESC-Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL-Cholangiocarcinoma; COAD-Colon adenocarcinoma; DLBC-Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; GBM-Glioblastoma multiforme; HNSC-Head and Neck squamous cell carcinoma; KICH-Kidney Chromophobe; KIRC-Kidney renal clear cell carcinoma; KIRP-Kidney renal papillary cell carcinoma; LGG-Brain Lower Grade Glioma; LIHC-Liver hepatocellular carcinoma; LUAD-Lung adenocarcinoma; LUSC-Lung squamous cell carcinoma; MESO-Mesothelioma; OV-Ovarian serous cystadenocarcinoma; PAAD-Pancreatic adenocarcinoma; PCPG-Pheochromocytoma and Paraganglioma; PRAD-Prostate adenocarcinoma; READ-Rectum adenocarcinoma; SARC-Sarcoma; SKCM-Skin Cutaneous Melanoma; STAD-Stomach adenocarcinoma; TGCT-Testicular Germ Cell Tumors; THYM-Thymoma; THCA-Thyroid carcinoma; UCS-Uterine Carcinosarcoma; UCEC-Uterine Corpus Endometrial Carcinoma; UVM-Uveal Melanoma
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.